301 studies found for:    Exclude Unknown | Expanded Access Studies
Show Display Options
Download search resultsDownload the search results for:
Exclude Unknown | Expanded Access Studies (301 records)
Download Content:
Zip file readers with free trial periods: WinZip or PKZip
Rank Status Study
1 Temporarily not available Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
Conditions: Multiple Sclerosis;   Autoimmune Diseases;   Disseminated or Multiple Sclerosis Nos;   Multiple Sclerosis, Acute Relapsing;   Multiple Sclerosis, Primary Progressive;   Multiple Sclerosis, Chronic Progressive
Intervention: Drug: Tetracycline - Statin - Antimycotic
2 Available Expanded Access Protocol to Provide Brincidofovir for the Treatment of Serious Adenovirus Infection or Disease
Condition: Adenovirus
Intervention: Drug: Brincidofovir
3 No longer available A Prospective, Multiparametric Biomarker Study to Identify Predictors of Treatment Response and Resistance in Patients With EGFR-mutated Non-small-cell Lung Cancer Receiving Maintenance Therapy With Either Afatinib or Pemetrexed With the AIO-TRK-0114 Study (MARBLE)
Condition: Non-small-cell Lung Cancer With Somatic EGFR Mutations
Intervention: Other: Collection of tumor and blood specimen
4 Available Deflazacort Expanded Access Program for Children, Adolescents and Adults With Duchenne Muscular Dystrophy
Condition: Duchenne Muscular Dystrophy
Intervention: Drug: Deflazacort
5 Available Compassionate Use Arm - ABI541 ABI for 10 NF2 Patients
Conditions: Neurofibromatosis Type 2;   Severe Profound Sensorineural Hearing Loss
Intervention: Device: Nucleus Profile ABI541 Auditory Brainstem Implant
6 Available An Expanded Access Study of MPDL3280A in Patients With PD-L1-Positive Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy
Condition: Urothelial Bladder Cancer
Intervention: Drug: MPDL3280A
7 Temporarily not available Autologous Platelet-rich Plasma (aPRP) for Complex Aortic Arch Surgerymacrovascular Operation
Condition: Autologous Blood Transfusion
Intervention: Procedure: Sorin XTRA/Sorin Group,
8 No longer available Compassionate Use of Aldoxorubicin in Sarcoma Patients Chemotherapy
Condition: Sarcoma
Intervention: Drug: aldoxorubicin
9 Available An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Panobinostat
10 Available Domperidone Expanded Access Protocol for Patients With Gastrointestinal Disorders
Condition: Refractory Gastroesophageal Reflux Disease With Upper Gastrointestinal (GI) Symptoms, Gastroparesis, and Chronic Constipation
Intervention: Drug: Domperidone
11 Available Cannabidiol for Pediatric Epilepsy (Compassionate Use)
Condition: Refractory Childhood Epilepsy
Intervention: Drug: cannabidiol (CBD)
12 Available Rociletinib (CO-1686) USA Expanded Access Program
Condition: Non-small Cell Lung Cancer
Intervention: Drug: Rociletinib
13 No longer available Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Elotuzumab
14 Available Study of the Use of [18F]-DOPA in Hyperinsulinemic Hypoglycemia
Conditions: Hyperinsulinemic Hypoglycemia, Persistent;   Congenital Hyperinsulinism;   Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)
Intervention: Drug: 18 F-DOPA
15 Available EAP of CPX-351 for Patients 60-75 Years of Age With Secondary AML
Condition: Secondary AML
Intervention: Drug: CPX-351
16 Available Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography
Conditions: Prostate Cancer;   Recurrent Prostate Cancer
Interventions: Drug: 11C-choline;   Device: PET/CT Scan
17 Temporarily not available Emergent Expanded Access for ahSC Augmentation of Nerve Autografts After Severe Peripheral Nerve Injury.
Condition: Sciatic Nerve Injury
Intervention: Biological: Autologous human Schwann cells
18 Available Triheptanoin (UX007) to Treat Citrate Transporter Deficiency
Conditions: Citrate Transporter Deficiency;   SLC13A5 Gene Mutation
Intervention: Drug: triheptanoin
19 Approved for marketing Expanded Access Program for Asfotase Alfa Treatment for Patients With Infantile- or Juvenile-onset Hypophosphatasia (HPP)
Condition: Hypophosphatasia
Intervention: Biological: asfotase alfa
20 Available Domperidone Expanded Access Program for Oncology Patients With Gastroparesis Who Have Failed Standard Therapy
Condition: Oncology Patients With Gastroparesis
Intervention: Drug: Oral Domperidone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years